{"classes":[{"categories":[{"measurements":[{"comment":"Values are not estimable as Median was not reached","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper limit was not estimable","groupId":"OG001","lowerLimit":"2.4","upperLimit":"NA","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Time from randomization and earliest of either (1) date of bone marrow blast count of 20% or greater; (2) date of first peripheral blast count of 20% or greater that was subsequently confirmed to sustain for at least 8 weeks; (3) date of death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule","id":"OG000","title":"Ruxolitinib"},{"description":"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) consisted of all subjects who were randomized and put in strata according to International Working Group for Myelofibrosis Research and Treatment(IWG MRT) prognostic criteria. Treatment groups were defined according to the treatment assignment at the time of randomization.","reportingStatus":"POSTED","timeFrame":"Time from randomization and earliest of either leukemia or death","title":"Leukemia-free Survival (LFS)","type":"SECONDARY","unitOfMeasure":"Years"}